Health Care • Biotechnology: Pharmaceutical Preparations
$1.96 ▼ -0.03
(-1.51%)
MKT CAP: $188.4M • VOL: 1.33M
52W L $1 52W H $7
ROARABLE / RQD
D- • 39/100
PIOTROSKI
3 / 9
ZNTL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $67.4M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$152.8M | -$191.2M | -$299.5M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$137.1M | -$165.9M | -$292.3M |
| EBITDA (Normalized) | -$152.8M | -$191.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$125.2M | -$170.9M | -$207.8M |
| Capital Expenditures (CapEx) | $0 | $221.0K | — |
| Free Cash Flow (FCF) | -$125.2M | -$171.1M | -$207.8M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $36.0M | $33.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $216.2M | $337.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZNTL.